Optibrium, a developer of software for drug discovery, has announced the appointment of Dr Peter Hunt as Director of Computational Chemistry.
Reflecting the growth in the business, Optibrium has expanded its R&D and operational teams to accelerate the rate of product development and support its growing customer base. This has required the company to extend its facilities by 50 per cent, less than two years after its last office expansion.
As part of the expansion of the R&D team, Dr Peter Hunt has joined as Director of Computational Chemistry, from Novartis, where he was Group Leader, Computer Aided Drug Discovery (CADD).
He has more than 25 years of experience in drug discovery, both in industry and academic research, having previously been CADD Group Leader at Merck and the 3D Centre in Australia. He will provide leadership on research efforts relating to Optibrium’s software and the EU funded HeCaToS project, and his extensive drug discovery experience will further support users of Optibrium’s software platforms.
Peter commented: ‘I am delighted to be joining Optibrium and contributing to the development of the StarDrop product and the research into hepatic and cardiac toxicity estimation funded through the EU.’ Dr Matthew Segall, Optibrium’s CEO, added: ‘We are very happy to welcome Peter to our team, which has maintained an impressive rate of innovation over the last 5 years as we expanded our customer base worldwide. The continued growth of Optibrium is a result of the team’s hard work and together we look forward to developing new solutions that will help scientists to improve the efficiency and productivity of drug discovery.’
